Differences

Last edited on January 2, 2024

This shows you the differences between two versions of the page.

--- teaching:apathy [on September 5, 2023]
psychdb [Pathophysiology]
+++ teaching:apathy [on January 2, 2024]
psychdb [Treatment]
@@ Line 25: / Line 25: @@
 ===== Treatment =====
   * [[meds:stimulants:2-methylphenidate:home|Methylphenidate]] has been shown to be useful in the treatment of apathy specifically in Alzheimer's disease.[([[https://pubmed.ncbi.nlm.nih.gov/34570180/|Mintzer, J., Lanctôt, K. L., Scherer, R. W., Rosenberg, P. B., Herrmann, N., Van Dyck, C. H., ... & ADMET 2 Research Group. (2021). Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. JAMA neurology.]])]
-    * Individuals who are not anxious or agitated, younger, already prescribed an acetylcholinesterase inhibitor, have optimal (73-80 mm Hg) diastolic blood pressure, or having more impaired function are more likely to benefit from methylphenidate compared to placebo. [([[https://pubmed.ncbi.nlm.nih.gov/37385898/|Lanctôt, K. L., Rivet, L., Tumati, S., Perin, J., Sankhe, K., Vieira, D., ... & Herrmann, N. (2023). Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial. The American Journal of Geriatric Psychiatry.]])]
+    * Individuals who are not anxious or agitated, younger, already on an acetylcholinesterase inhibitor, have optimal diastolic blood pressure control (73-80 mm Hg), or more impaired function are more likely to benefit from treatment. [([[https://pubmed.ncbi.nlm.nih.gov/37385898/|Lanctôt, K. L., Rivet, L., Tumati, S., Perin, J., Sankhe, K., Vieira, D., ... & Herrmann, N. (2023). Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial. The American Journal of Geriatric Psychiatry.]])]
 ===== Resources =====